dc.contributor.author | Beton, Osman | |
dc.contributor.author | Asarcikli, Lale Dinc | |
dc.contributor.author | Sen, Taner | |
dc.contributor.author | Ipek, Esra Gucuk | |
dc.contributor.author | Kafes, Habibe | |
dc.contributor.author | Yaman, Mehmet | |
dc.contributor.author | Efe, Tolga Han | |
dc.contributor.author | Kaya, Hakki | |
dc.contributor.author | Temizhan, Ahmet | |
dc.contributor.author | Yilmaz, Mehmet Birhan | |
dc.date.accessioned | 2019-07-27T12:10:23Z | |
dc.date.accessioned | 2019-07-28T09:44:24Z | |
dc.date.available | 2019-07-27T12:10:23Z | |
dc.date.available | 2019-07-28T09:44:24Z | |
dc.date.issued | 2017 | |
dc.identifier.issn | 0031-7012 | |
dc.identifier.issn | 1423-0313 | |
dc.identifier.uri | https://dx.doi.org/10.1159/000449389 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12418/7049 | |
dc.description | WOS: 000393268700003 | en_US |
dc.description | PubMed ID: 27654487 | en_US |
dc.description.abstract | Aim: We aimed to evaluate the effect of echocardiographically demonstrated right ventricular dysfunction (RVD) on time in therapeutic range (TTR) in heart failure (HF) patients receiving warfarin therapy. Methods:A total of 893 consecutive HF patients were included and classified into 4 different subgroups: HF with preserved ejection fraction (HFpEF) without RVD (n = 373), HF with reduced EF (HFrEF) without RVD (n = 215), HFpEF with RVD (n = 106) and HFrEF with RVD (n = 199). Groups were compared according to baseline, demographic and clinical data and the characteristics of warfarin therapy. Results: Presence of RVD yielded lower median TTR values both in HFpEF and HFrEF patients. RVD, current smoking, New York Heart Association functional class III/IV, hypertension, diabetes mellitus, pulmonary disease, prior transient ischemic attack or stroke, chronic kidney disease (CKD) stage 4/5 and CKD stage 3 were found to be independent predictors of poor anticoagulation control in multivariate logistic regression analysis. Conclusions: The present study demonstrated that presence of RVD in HF increases the risk for poor anticoagulation. (C) 2016 S. Karger AG, Basel | en_US |
dc.language.iso | eng | en_US |
dc.publisher | KARGER | en_US |
dc.relation.isversionof | 10.1159/000449389 | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Warfarin | en_US |
dc.subject | Heart failure | en_US |
dc.subject | Right ventricular dysfunction | en_US |
dc.subject | Time in therapeutic range | en_US |
dc.title | Right Ventricular Dysfunction Complicates Time in Therapeutic Range in Heart Failure Patients Receiving Warfarin | en_US |
dc.type | article | en_US |
dc.relation.journal | PHARMACOLOGY | en_US |
dc.contributor.department | [Beton, Osman -- Kaya, Hakki -- Yilmaz, Mehmet Birhan] Cumhuriyet Univ, Dept Cardiol, Ctr Heart, Univ Hosp, TR-58140 Sivas, Turkey -- [Asarcikli, Lale Dinc -- Efe, Tolga Han] Diskapi Yildirinn Beyazit Res & Training Hosp, Dept Cardiol, Polatli, Turkey -- [Ipek, Esra Gucuk] Polatli State Hosp, Dept Cardiol, Polatli, Turkey -- [Kafes, Habibe -- Temizhan, Ahmet] Turkiye Yuksek Ihtisas Res & Training Hosp, Dept Cardiol, Ankara, Turkey -- [Sen, Taner] Dumlupinar Univ, Dept Cardiol, Kutahya, Turkey -- [Yaman, Mehmet] Samsun Res & Training Hosp, Dept Cardiol, Samsun, Turkey | en_US |
dc.contributor.authorID | YILMAZ, Mehmet Birhan -- 0000-0002-8169-8628; YILMAZ, MEHMET BIRHAN -- 0000-0002-8169-8628 | en_US |
dc.identifier.volume | 99 | en_US |
dc.identifier.issue | 01.Feb | en_US |
dc.identifier.endpage | 26 | en_US |
dc.identifier.startpage | 19 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |